Fig. 4: Outcomes of patients with de novo acute myeloid leukemia categorized according to the presence or absence of myelodysplasia-related mutations. | Leukemia

Fig. 4: Outcomes of patients with de novo acute myeloid leukemia categorized according to the presence or absence of myelodysplasia-related mutations.

From: Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

Fig. 4

a Disease-free survival and b overall survival of patients with myelodysplasia-related mutations with and those without favorable-risk AML subtypes, and of patients in the 2022 ELN adverse group who do not harbor myelodysplasia-related mutations. c Disease-free survival and d overall survival of patients in the 2022 ELN favorable group with myelodysplasia-related mutations and favorable-risk AML subtypes, and of patients in the 2022 ELN favorable group who do not have myelodysplasia-related mutations. e Disease-free survival and f overall survival of patients in the 2022 ELN favorable group with NPM1 mutations, no FLT3-ITD and myelodysplasia-related mutations, and of patients in the 2022 ELN favorable group with NPM1 mutations without FLT3-ITD or myelodysplasia-related mutations.

Back to article page